A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to eValuate the effIcacy and safeTy of the orAL sGC stImulator vericiguaT to improve phYsical functioning in activities of daily living in patients with heart failure and preserved ejection fraction (VITALITY-HFpEF)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Vericiguat (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms VITALITY-HFpEF
- Sponsors Bayer
- 19 Oct 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
- 21 May 2019 Planned End Date changed from 15 Jan 2020 to 12 Nov 2019.
- 21 May 2019 Planned primary completion date changed from 16 Dec 2019 to 11 Oct 2019.